# Blueprint Medicines Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blueprint-medicines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.blueprintmedicines.com
- Total disclosed funding: $113M
- Latest round: Series C (Nov 10, 2014)
- Investors on record: 13

## About

Blueprint Medicines Corporation is a biopharmaceutical company dedicated to developing targeted therapies for rare diseases, particularly in oncology and immunology, addressing significant unmet medical needs and improving patient outcomes.Blueprint Medicines Corporation, founded in 2011, is headquartered in Cambridge, US. The company specializes in targeted therapies for rare diseases. Its founder, Alexis Borisy, has a history of founding other companies in the biopharmaceutical sector. As of March 2019, Blueprint Medicines has raised a total of USD 9,100.00 mn through several funding rounds, with the most recent being a PIPE round totaling USD 1,250.00 mn, involving investors such as Royalty Pharma and Sixth Street (Growth).Blueprint Medicines Corporation specializes in developing targeted therapies for patients with rare diseases, focusing on mast cell disorders and specific cancers. Their flagship product, AYVAKIT® (avapritinib), is approved for treating indolent and advanced systemic mastocytosis and unresectable or metastatic gastrointestinal stromal tumors with specific mutations. The company serves healthcare providers and patients primarily in the oncology and immunology sectors across the United States and Europe.In 2023, Blueprint Medicines Corporation reported a revenue of USD 249.38 mn. The company generates revenue through sales of its proprietary therapies, with a focus on direct sales to healthcare providers. Their revenue structure ensures that patients have access to innovative treatments through individual prescriptions and partnerships with pharmaceutical distributors and healthcare organizations. The company reported an EBITDA of USD -475.56 mn for the same year.Blueprint Medicines Corporation aims to utilize the funding from its most recent PIPE round to enhance clinical trials for its lead product candidates and to further develop its kinase discovery platform. As part of its growth strategy, the company is focusing on the launch of upcoming products and expanding its market reach into new geographic regions. Specific target markets and timelines for these initiatives are not detailed but are aligned with the company’s commitment to addressing unmet medical needs.

## Funding rounds

- Series C, Nov 10, 2014, $50M — F-Prime Capital, Wellington Management, Third Rock Ventures, Nextech, Tavistock Group, Redmile Group, Casdin Capital, BVF Partners, RA Capital Management, Sabby Capital, Partner Fund Management, Cowen Investment Management, Perceptive Advisors
- Series B, Jan 8, 2014, $23M — F-Prime Capital, Third Rock Ventures, Nextech, Casdin Capital
- Series A, Sep 5, 2013, $15M — Third Rock Ventures
- Series A, Feb 7, 2012, $10M — F-Prime Capital, Third Rock Ventures
- Series A, Apr 11, 2011, $15M — F-Prime Capital, Third Rock Ventures

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series C
- Partner Fund Management — Series C
- Cowen Investment Management — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C